GlaxoSmithKline liberalizes release of clinical trial data

October 11th, 2012 by Staff

GlaxoSmithKline (GSK), the manufacturer of pazopanib (Votrient), announced Thursday, October 11th that they make detailed data from their clinical trials available to researchers. These data presumably were not all available before, either to drug approval agencies (the Food and Drug Administration and the European Medicines Agency) or to external researchers. This release applies to drugs that have already been approved or ones for whose research has been discontinued.

The objective on the part of GSK is to be more transparent. GSK was fined $3 billion this summer by the US Justice Department due to its withholding of information about increased risk for heart failure and heart attack during use of its anti-diabetes drug Avandia.

People are hopeful that the release of full clinical data could lead external researchers to develop more effective drugs, or, at least, provide a full side-effect profile that was not heretofore available for current drugs. If this new policy were to be followed by other drug companies, this would help oncologists make better choices about which drugs of similar efficacy to prescribe to cancer patients based on the side effects of the drug and the health issues of individual patients.

Note that GSK, in a previous effort at transparency, started reporting on their current trial protocols and summaries of results, including renal cell carcinoma, on their website at http://www.gsk-clinicalstudyregister.com/.

8 Responses to “GlaxoSmithKline liberalizes release of clinical trial data”

  1. April 27, 2014 at 2:57 pm, Bonnie said:

    I just completed a clinical trial with Glaxo …Votrient, double-blind study for stage 3 rcc. I DID receive the drug and went from 600 mg down to 200mg by the end ofthe yr long study. Praying this helps to stave off all return of cancer as well as help others in same regard.

    Reply

  2. June 15, 2014 at 4:47 am, trening said:

    Thank you a lot for sharing this with all of us you really recognize what you are
    talking approximately! Bookmarked. Please additionally seek advice from my website =).
    We may have a link trade agreement among us

    Reply

  3. June 16, 2014 at 1:38 am, zawodnicy fitness said:

    It is perfect time to make some plans for the longer term and it’s time to be happy.
    I have learn this post and if I could I want to recommend you few interesting issues or tips.

    Perhaps you could write next articles referring to this article.
    I want to learn even more things approximately it!

    Reply

  4. June 16, 2014 at 3:11 am, silownia trening said:

    Nice post. I was checking constantly this blog and I
    am impressed! Extremely useful information specially the last part :
    ) I care for such info a lot. I was looking for this particular information for a long time.
    Thank you and best of luck.

    Reply

  5. June 20, 2014 at 8:35 am, suplementy i odzywki said:

    I always emailed this weblog post page to all my associates, for
    the reason that if like to read it then my friends will too.

    Reply

  6. October 14, 2014 at 3:01 am, Savannah said:

    Hi there just wanted to give you a quick heads up and let
    you know a few of the images aren’t loading correctly.
    I’m not sure why but I think its a linking issue. I’ve tried it
    in two different browsers and both show the same outcome.

    Reply

  7. October 16, 2014 at 4:00 am, Kareem said:

    Excelleent way off describing, aand fastidious paragraph to get innformation regarding mmy presentation subject, whicch i am gong tto delijver in university.

    Reply

  8. October 16, 2014 at 8:14 pm, Linette said:

    It’s remarkable to pay a visit this web page and reading the views of all colleagues on the topic
    of this post, while I am also zealous of getting know-how.

    Reply

Leave a Reply